GlassScriptPhysician profile
Harold F Farber
NPI 1194833590
$284,075.54
in general payments reported to CMS, 2019-2025
46 companies · $40K in 2025
The $40K reported for 2025 was more than what 96% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70K · 2020: $34K · 2021: $36K · 2022: $8,137 · 2023: $44K · 2024: $52K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $56K · Consulting Fee: $40K · Honoraria: $23K · Food and Beverage: $10K · Travel and Lodging: $7,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $56,241.26 |
| Consulting Fee | $39,675.00 |
| Honoraria | $23,200.00 |
| Food and Beverage | $10,037.16 |
| Travel and Lodging | $7,274.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $65,082.73 | 2019-2025 | Winlevi, Absorica Ld, Ilumya |
| Dermavant Sciences, INC. | $40,816.03 | 2022-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $31,858.53 | 2023-2024 | Zoryve |
| Organon LLC | $25,296.03 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21,179.00 | 2019-2024 | Retin-A, Siliq, Altreno |
| Almirall LLC | $20,746.48 | 2019-2025 | Klisyri |
| Galderma Laboratories, L.P. | $15,776.12 | 2019-2025 | Nemluvio, Aklief |
| Verrica Pharmaceuticals INC. | $13,089.30 | 2023-2025 | Ycanth |
| Senseonics, Incorporated | $8,320.00 | 2019-2020 | |
| Biofrontera INC. | $6,178.59 | 2019-2025 | Ameluz |
| Pfizer INC. | $4,660.61 | 2019-2025 | |
| Epi Health, LLC | $3,832.00 | 2019-2022 | |
| Ucb, INC. | $3,632.49 | 2021-2025 | Bimzelx, Cimzia |
| Mayne Pharma Commercial LLC | $3,354.16 | 2019-2025 | |
| Vyne Pharmaceuticals INC. | $3,240.96 | 2020-2021 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Farber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.